
Jon Mochel
Skills
Experience
COO @3D Health Solutions • Co-Founder
Jan '18 - Present (3 years 1 month)
Associate Professor @Iowa State University • Employee
Oct '16 - Present (4 years 4 months)
Scientific cofounder @LEAH Labs • Co-Founder
LEAH Labs is curing cancer in dogs
Amazing things Jon's made
Education

Leiden University
Pharmacometrics • 2010 - 2015

European College of Veterinary Pharmacol
Pharmacology Residency • 2009 - 2013

Université Toulouse III Paul Sabatier
Pharmacology • 2006 - 2008

Paris
Veterinary Medicine • 2002 - 2007
Recommendations
Spencer Stensrude CEO at Ag Ventures Alliance recommended LEAH Labs where Jon is Co-Founder
Wes started LEAH Labs straight out of a Ph.D. program. He has applied his ability to learn complex topics quickly to leading a startup.
The team at LEAH Labs is working at the cutting edge of cell therapy and has taken an approach that could allow this company to be the key to unlocking an entire category of advanced, personalized medicine.
Every time I speak with Wes, I get more excited about where this company is going.
Spencer Stensrude CEO at Ag Ventures Alliance recommended LEAH Labs where Jon is Co-Founder
Joel Harris recommended LEAH Labs where Jon is Co-Founder
I am co-Director at Ag Startup Engine, a Midwest seed fund aimed at funding early stage AgTech companies in the Midwest. At Ag Startup Engine, we are uniquely focused on the success of early, seed-stage companies. LEAH Labs is our eighth investment. We hold monthly roundtable discussions for our portfolio businesses to interact and learn from each other. It also provides a time for sharing successes and challenges in a supportive group environment. Additionally, Ag Engine’s reach to other investment groups is broad.
It is our goal to help LEAH Labs build a pathway to gaining additional investors (Series A). We chose to fund LEAH Labs because we know 6,000,000 dogs die of cancer every year in the United States alone and the market is ripe for innovative, high-tech solutions. LEAH Labs uses licensed, patent-pending technology that enables reprogramming immune cells into cancer fighting machines.